NANOVIRICIDES, INC. (NNVC): Entry into a Material Definitive Agreement
NANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2620770d1_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 NANOVIRICIDES, INC. Common Stock (par value $0.00001 per share) At Market Issuance Sales Agreement July 17, 2026 D. Boral Capital LLC 590 Madison Avenue, 39 th Floor New York, New York 10022 Ladies and Gentlemen: NanoViricide
How this was made
The 30-second read
Why it matters
The agreement allows NanoViricides to sell common shares through an agent during the term of the program, subject to registration statement and prospectus supplement limits.
Market read
This is a fresh capital-markets disclosure that can change dilution expectations and near-term valuation for NNVC.
What to watch
Traders should check the prospectus supplement and any stated use of proceeds, as well as whether the ATM includes price limits or conditions that constrain dilution.
Background
The 8-K reports Item 1.01, entry into a material definitive agreement, specifically an at-the-market (ATM) common stock sales agreement.
Ticker impact
NanoViricides entered an at-the-market sales agreement with D. Boral Capital LLC to issue and sell common shares from time to time.
Near-term pressure possible if investors price in potential dilution; magnitude depends on how much stock is sold under the ATM.
An ATM program enables incremental share sales without a separate announcement each time, typically viewed as dilutive. The 8-K is the first disclosure of the agreement, but the filing excerpt does not state the size or expected pace of sales.
Market effects
Highlights ongoing financing needs typical of small-cap biotech, potentially reinforcing risk-off sentiment toward similar issuers.
Primarily impacts US small-cap biotech trading and liquidity expectations.
Limited direct global spillover; mostly company-specific capital structure news.
Counterpoint
If proceeds fund specific catalysts (trials, approvals, commercialization), the ATM could be interpreted as enabling growth rather than signaling distress.
Key entities
- issuerNanoViricides, Inc.
Subject of the 8-K and counterparty to the ATM sales agreement.
- agentD. Boral Capital LLC
Sales agent or principal under the at-the-market issuance agreement.
